IL-17F Antibody, anti-human, REAfinity™
Synonyms: Interleukin-17F, CANDF6, ML-1
RECOMBINANT EXTENDED VALIDATION
Clone:
REA1012 | LN2-9C4.4
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for IL-17F Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
Vio B515
Description:
Latex beads were coated with recombinant human IL-17F protein and then stained with IL-17F antibodies or with the corresponding REA control (I) antibodies (left peak). Flow cytometry was performed with the MACSQuant® Analyzer.
Intracellular flow cytometry applications
APC
FITC
PE
Vio B515
Vio R667
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-116-990, 130-116-870
Description:
CD4+ T cells were isolated from human peripheral blood mononuclear cells (PBMCs). Cells were then stimulated with 50 ng/mL Phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml Ionomycin for 6 hours and then positively selected for their IL-17A expression. After cultivation for 11 days, cells were restimulated with 50 ng/mL PMA and 1 µg/ml Ionomycin for 6 hours, followed by an incubation with 1 µg/ml Brefeldin A for 4 hours. Cells were then fixed, permeabilized and stained with the REA Control (I) antibodes (left image) or with Anti-IL-17F antibodies. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application imageView details view details

Application imageView details view details
Extended validation for IL-17F Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA1012
O33-782
high
SHLR17
high
LN2-9C4
high

Cells were incubated with an excess of purified unconjugated IL-17F (REA1012) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for IL-17F. Human peripheral blood mononuclear cells (PBMCs) were stimulated with 20 ng/mL Phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml Ionomycin for 1 hour, followed by an incubation with 1µg/mL Brefeldin A for 5 hours. Cells were first stained with Viobility™ Fixable Dye followed by a suitable counterstaining. Cells were then fixed and permeabilized followed by a staining with IL-17F antibodies. As a control, IL-17F antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD3+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and Viobility 405/520 Fixable Dye fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Specifications for IL-17F Antibody, anti-human, REAfinity™
Overview

Clone REA1012 recognizes the human interleukin 17F (IL-17F) antigen, a homodimeric, 34 kDa member of the IL-17 family, which includes IL-17A, IL-17B, IL-17C, IL-17D, and IL-17E (also called IL-25). Interleukin 17 functions as a proinflammatory cytokine that responds to the invasion of the immune system by extracellular pathogens and induces destruction of the pathogen’s cellular matrix. Phylogenetic analysis reveals that among IL-17 family members, the IL-17F isoforms 1 and 2 (ML-1) have the highest homology to IL-17A (sharing 55 and 40% amino acid identity to IL-17A). IL-17F has been shown to have a pro-inflammatory role in asthma. It is expressed in the airway of asthmatics and its expression level is correlated with disease severity. IL-17F is able to induce several cytokines, chemokines and adhesion molecules in bronchial epithelial cells, vein endothelial cells, fibroblasts, and eosinophils. It is derived from several cell types such as T helper 17 (Tʜ17) cells, mast cells and basophils, and shows a wide tissue expression pattern including lung. Overexpression of the IL-17F gene in the airway of mice is associated with airway neutrophilia, the induction of many cytokines, an increase in airway hyperreactivity, and mucus hypersecretion. Hence, IL-17F may have a crucial role in allergic airway inflammation, and have important therapeutic implications in asthma.

Additional information: Clone REA1012 displays negligible binding to Fc receptors.

Alternative names

Interleukin-17F, CANDF6, ML-1

Detailed product information

Technical specifications

Clone
REA1012
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
IL-17F
Molecular mass of antigen [kDa]
15
Distribution of antigen
granulocytes, mast cells, T cells, basophils
Entrez Gene ID
RRID
AB_2727729, AB_2727799, AB_2727800, AB_2727730, AB_2727731, AB_2727798, AB_2727728, AB_2727801

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for IL-17F Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for IL-17F Antibody, anti-human, REAfinity™
Publications
  1. Kawaguchi, M. et al. (2009) Role of interleukin-17F in asthma. Inflamm Allergy Drug Targets 8 (5): 383-389
  2. Starnes, T. et al. (2001) Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 167 (8): 4137-4140
  3. Yang, X. O. et al. (2008) Regulation of inflammatory responses by IL-17F. J. Exp. Med. 205 (5): 1063-1075

You have previously chosen International as your location.
What do you want to do?